Critical role for prokineticin 2 in CNS autoimmunity
Authors:
- Mhamad Abou-HamdanMAMhamad Abou-Hamdan
- Massimo CostanzaMCMassimo Costanza
- Elena FontanaEFElena Fontana
- Marco Di DarioMDMarco Di Dario
- Silvia MusioSMSilvia Musio
- Cenzo CongiuCCCenzo Congiu
- Valentina OnnisVOValentina Onnis
- Roberta LattanziRLRoberta Lattanzi
- Marta RadaelliMRMarta Radaelli
- Vittorio MartinelliVMVittorio Martinelli
- Severo SalvadoriSSSevero Salvadori
- Lucia NegriLNLucia Negri
Open Access
- 1 June 2015
- journal article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 2 (3) , e95
Abstract
Objective: To investigate the potential role of prokineticin 2 (PK2), a bioactive peptide involved in multiple biological functions including immune modulation, in CNS autoimmune demyelinating disease. Methods: We investigated the expression of PK2 in mice with experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), and in patients with relapsing-remitting MS. We evaluated the biological effects of PK2 on expression of EAE and on development of T-cell response against myelin by blocking PK2 in vivo with PK2 receptor antagonists. We treated with PK2 immune cells activated against myelin antigen to explore the immune-modulating effects of this peptide in vitro. Results: Pk2 messenger RNA was upregulated in spinal cord and lymph node cells (LNCs) of mice with EAE. PK2 protein was expressed in EAE inflammatory infiltrates and was increased in sera during EAE. In patients with relapsing-remitting MS, transcripts for PK2 were significantly increased in peripheral blood mononuclear cells compared with healthy controls, and PK2 serum concentrations were significantly higher. A PK2 receptor antagonist prevented or attenuated established EAE in chronic and relapsing-remitting models, reduced CNS inflammation and demyelination, and decreased the production of interferon (IFN)-γ and interleukin (IL)-17A cytokines in LNCs while increasing IL-10. PK2 in vitro increased IFN-γ and IL-17A and reduced IL-10 in splenocytes activated against myelin antigen. Conclusion: These data suggest that PK2 is a critical immune regulator in CNS autoimmune demyelination and may represent a new target for therapy.Keywords
This publication has 39 references indexed in Scilit:
- Controlling the activation of the Bv8/prokineticin system reduces neuroinflammation and abolishes thermal and tactile hyperalgesia in neuropathic animalsBritish Journal of Pharmacology, 2014
- Prolactin Is Not Required for the Development of Severe Chronic Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2013
- Multiple sclerosis and glutamate excitotoxicityReviews in the Neurosciences, 2013
- Progressive multiple sclerosis: pathology and pathogenesisNature Reviews Neurology, 2012
- Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidenceMultiple Sclerosis Journal, 2012
- Bv8/PK2 and prokineticin receptors: a druggable pronociceptive systemCurrent Opinion in Pharmacology, 2012
- Autoimmune T cell responses in the central nervous systemNature Reviews Immunology, 2009
- The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1BMC Immunology, 2008
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophagesBritish Journal of Pharmacology, 2006